Update on the management of inflammatory bowel disease: specific role of adalimumab
Luisa Guidi, Daniela Pugliese, Alessandro ArmuzziInternal Medicine and Gastroenterology, Complesso Integrato Columbus, Università Cattolica del Sacro Cuore, Rome, ItalyAbstract: Anti-tumor necrosis factor alpha (TNF-a) medications are a class of biologics employed in the treatment of...
Main Authors: | Guidi L, Pugliese D, Armuzzi A |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2011-07-01
|
Series: | Clinical and Experimental Gastroenterology |
Online Access: | http://www.dovepress.com/update-on-the-management-of-inflammatory-bowel-disease-specific-role-o-a7879 |
Similar Items
-
Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab
by: Armuzzi A, et al.
Published: (2013-04-01) -
Frontiers in Drug Research and Development for Inflammatory Bowel Disease
by: Diego Currò, et al.
Published: (2017-06-01) -
Adalimumab for treatment of very early onset inflammatory bowel disease
by: Yao Xie, et al.
Published: (2019-12-01) -
Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases
by: Giuseppe Privitera, et al.
Published: (2021-02-01) -
Adherence to treatment with adalimumab, golimumab and ustekinumab in patients with inflammatory bowel disease
by: María Calvo-Arbeloa, et al.
Published: (2020-03-01)